Therapy Areas: Infectious Diseases
Arrevus acquires fusidic acid from Melinta Therapeutics for undisclosed amount
6 February 2019 -

Novel therapeutics company Arrevus Inc revealed on Tuesday the completion of the acquisition of fusidic acid from Melinta Therapeutics for undisclosed fee.

Melinta Therapeutics (www.melinta.com) is reportedly a commercial-stage company dedicated to developing and commercialising novel antibiotics to treat serious bacterial infections and currently has four US FDA-approved antibiotics.

The fusidic acid is an antibiotic with more than 50 years clinical experience outside the US and is under development for the treatment of ABSSSI and refractory bone and joint infections. Fusidic acid is orally active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus strains (MRSA).

Following the acquisition, Arrevus is better positioned to advance its pipeline into clinical use for patients with serious bacterial infections with substantial unmet need.

A phase 3 clinical trial in patients with ABSSSI demonstrated a tolerability profile and efficacy comparable to linezolid. About 60% of patients with refractory bone and joint infection were clinical successes after six months of oral fusidic acid treatment. Fusidic acid received Orphan Drug Designation from the US FDA for prosthetic joint infection as well as Qualified Infectious Disease Product Designation under the Generating Antibiotic Incentives Now (GAIN) Act, revealed the company.

Login
Username:

Password: